Ascendis Pharma (ASND) Reports Q3 Loss of EUR0.30/Share

Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR0.30), versus (EUR0.18) reported last year. Revenue for the quarter came in at EUR2.1 million, versus EUR3.3 million reported last year.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Wolverine World Wide (WWW) Tops Q2 EPS by 2c; offers guidance
• Applied Industrial Technologies (AIT) Tops Q4 EPS by 25c, Beats on Revenue; Offers FY27 EPS Guidance
• Pluralsight (PS) Reports Q2 EPS of $0.14